Program:

10.00 – 11.00: Regulatory perspectives

[TBC]	**New IVD Regulations: impact on health institutions**
Andy Rawstron	**MRD as an intermediate licensing endpoint: lessons from CLL & Myeloma**

11.00 – 11.30: Refreshment break

11.30 – 12.30: Academic laboratory perspectives: strategies for developing and applying clinically relevant assays

Vincent Van Der Velden	**Euroflow/EuroMRD in acute leukemia: flow, PCR or both?**
Gerrit Schuurhuis	**AML MRD – total disease burden or leukemic stem cells?**
Ruth de Tute	**Myeloma MRD: ICCS/ESCCA consensus**
TBC	**Laboratory analysis of pathway inhibitors**

12.30 – 13.30: Lunch break

13.30 – 14.30: pharmaceutical company perspectives - focus on the needs of the pharmaceutical industry that can be provided by academic laboratories and biotech companies

[TBC Emma Arriola]	**Scientific Director, Oncology Development, Abbvie**
Paul Sherrington	**Senior Director, Medical Affairs, Celgene**
Sharon McBain	**Senior Director, Global Regulatory Affairs, Oncology, Janssen**
Kirsten Mundt	**Oncology Biomarker Development, Roche**

14.30 – 15.00: Refreshment break

15.00 – 16.00: biotech company perspectives - focus on the challenges of turning a laboratory assay into a diagnostic kit

Jesper Kuhnau	**Agilent: Improving disease detection during/after antibody therapy**
Silvana Compasso	**BD Biosciences: from Euroflow to OneFlow**
Michael Kapinsky	**Beckman Coulter: Purpose-built RE (Rare Event) Duraclone Panels**

16.00 – 16.30: wrap-up & future directions